查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974127

COX-2選擇性非類固醇消炎劑（NSAIDs）市場：依給藥途徑、劑型、產品、適應症、通路和最終用戶分類－2026-2032年全球預測

COX-2 Selective NSAIDs Market by Route, Dosage Form, Product, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，COX-2 選擇性非類固醇消炎劑(NSAID) 市場價值將達到 86.6 億美元，到 2026 年將成長至 91.5 億美元，到 2032 年將達到 127.8 億美元，年複合成長率為 5.71%。

主要市場統計數據
基準年 2025 86.6億美元
預計年份：2026年 91.5億美元
預測年份 2032 127.8億美元
複合年成長率 (%) 5.71%

對現代醫學中選擇性 COX-2 抑制劑策略的治療作用、不斷演變的安全性概況和商業性格局進行了權威概述。

自問世以來，選擇性COX-2抑制劑佔據了獨特的治療領域，它們在提供針對抗發炎和鎮痛作用的同時，旨在降低非選擇性非類固醇抗發炎藥（NSAIDs）相關的胃腸道毒性。其研發和商業化路徑受到不斷變化的安全性特徵、監管要求以及臨床實踐模式轉變的影響。隨著臨床醫生在療效與心血管和腎臟風險之間尋求平衡，產品差異化越來越側重於製劑、給藥途徑和真實世界安全性證據。

簡要概述了推動 COX-2 選擇性治療領域結構變化和策略重組的關鍵臨床、商業性和監管因素。

在COX-2選擇性非類固醇抗發炎藥領域，正在發生多項變革性變化，這些變化正在重新定義研發重點和商業化策略。臨床證據的產生不再局限於基礎試驗，而是更加重視真實世界安全性監測和縱向心血管結局研究，這一轉變正在影響藥物的採納決策和處方醫生的信心。創新不再局限於新型化合物，而是擴大涵蓋製劑改進、替代給藥系統以及旨在擴大現有藥物臨床效用並降低安全性風險的聯合療法。

基於證據評估美國在 2025 年實施的關稅措施對 COX-2 選擇性藥物的供應鏈經濟、採購決策和分銷韌性的影響。

貿易和關稅體系的政策變化會對整個藥品供應鏈產生重大影響。美國在2025年宣布或實施的關稅措施為製造商、經銷商和醫療保健機構帶來了新的考量。針對藥品原料藥、輔料或成品的關稅措施會加劇投入成本的波動，並削弱依賴國際供應商的生產商的利潤率穩定性。這項變更促使許多機構重新評估供應商的地理分佈，增加關鍵投入品的庫存緩衝，並探索替代物流方案以維持供應的連續性。

對給藥途徑、劑型、產品系列、適應症、通路和最終用戶決策環境等多面向細分因素進行詳細解讀。

細分市場分析揭示了給藥途徑、劑型、產品選擇、適應症、分銷管道和終端用戶趨勢等因素如何共同塑造選擇性COX-2抑制劑療法的策略重點。基於給藥途徑，市場分為三個細分市場：注射劑、口服劑和外用劑。這三個觀點闡明了臨床定位：注射劑適用於急診護理和手術應用，口服劑適用於慢性門診治療，外用劑適用於局部疼痛管理，每種劑型的安全性和依從性特徵各不相同。基於劑型，市場分為膠囊劑、懸浮液和錠劑三個細分市場。這些劑型會影響依從性、病人偏好和生產複雜性。速釋片或緩釋片的設計可能會改變關於給藥頻率和健保報銷的討論。

實際的區域分析揭示了法規結構、准入趨勢和製造地如何在全球市場中創造差異化的機會和風險。

區域趨勢持續對COX-2選擇性抑制劑的臨床應用、法規要求和供應鏈設計產生重大影響。在美洲，與監管機構和支付方的談判中，成本效益和真實世界療效證據備受重視；同時，數位處方箋和網路藥局管道的快速普及正在改變患者的用藥模式，尤其是在美國市場。鑑於近期貿易政策的變化，北美生產和分銷基礎設施的韌性日益凸顯，相關人員的參與也越來越側重於透過藥物監測數據的透明度和與支付方的合作來衡量療效。

對製造商和經銷商如何利用產品組合創新、證據產生和供應鏈韌性來保護和擴大其市場地位進行簡明策略回顧。

製造商、合約開發商和分銷合作夥伴之間的競爭日益取決於產品組合的靈活性、證據產生能力和供應鏈的成熟度。領先的製藥公司和學名藥生產商正致力於透過改進製劑、採用緩釋技術以及拓展監管管道允許的適應症來最佳化產品生命週期管理。與契約製造製造商和專業經銷商建立策略合作夥伴關係，能夠實現注射劑和新型外用製劑的快速大規模生產，而內部研發能力對於維護知識產權相關的製程優勢和確保品管仍然至關重要。

一系列優先考慮的可操作建議，旨在加強供應鏈韌性、產生證據並實現 COX-2 抑制劑的商業性差異化。

產業領導者應採取一系列切實有效的措施，以協調臨床價值、營運韌性和商業性可行性。首先，應實現關鍵中間體和成品供應商網路的多元化，以降低地緣政治因素和關稅相關干擾的影響，並透過合約實施保障措施，確保前置作業時間和品質標準。同時，投資雙重採購和區域製造方案，將降低單一故障點的風險，並增強對需求波動的應對力。

一個透明且可重複的混合方法研究框架，結合了專家訪談、監管審查、臨床文獻整合和供應鏈映射。

本研究方法結合了定性和定量技術，以驗證基於多個互補資料流的見解。研究人員首先對臨床醫生、採購負責人、監管專家和商業負責人進行了結構化訪談，以此作為主要資訊來源，收集有關處方行為、藥物採納標準和供應鏈限制的實地資訊。其次，研究人員查閱了同行評審文獻、監管指導文件、臨床試驗註冊資訊和公共藥物監測資料庫，以對安全訊號和治療定位進行三角驗證。

簡而言之，為了維持選擇性 COX-2 抑制劑的可近性和價值，需要強調在臨床可靠性與營運和商業性靈活性之間取得平衡。

選擇性COX-2抑制劑在疼痛和發炎管理領域仍佔據著重要的策略地位，但其未來的發展軌跡並非由單一因素決定，而是取決於安全性證據、供應可靠性、監管預期以及不斷變化的給藥途徑等因素的相互作用。透過最佳化製劑和給藥途徑來實現臨床差異化，以及嚴格的真實世界安全性監測，對於維持處方醫師的信心至關重要。同時，商業性成功取決於能夠應對政策和地緣政治衝擊的穩健籌資策略和適應性分銷模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：COX-2選擇性非類固醇消炎劑（NSAID）市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用製劑

第9章：依上市劑型分類的COX-2選擇性非類固醇消炎劑（NSAIDs）

  • 膠囊
  • 懸浮液
  • 藥片

第10章：COX-2選擇性非類固醇消炎劑（NSAIDs）市場：依產品分類

  • 塞來昔布
  • 依曲昔布
  • 羅非昔布
  • 伐地考昔

第11章：COX-2選擇性非類固醇消炎劑（NSAID）市場：依適應症分類

  • 僵直性脊椎炎
  • 骨關節炎
  • 類風濕性關節炎

第12章：COX-2選擇性非類固醇消炎劑（NSAIDs）市場：依通路分類

  • 醫院藥房
  • 網路藥房
    • 廠商直銷
    • 第三方電商零售商
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第13章：COX-2選擇性非類固醇消炎劑（NSAIDs）市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 居家醫療
  • 醫院
    • 私人的
    • 民眾

第14章：COX-2選擇性非類固醇消炎劑（NSAID）市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：COX-2選擇性非類固醇消炎劑（NSAIDs）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：COX-2選擇性非類固醇消炎劑（NSAID）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國COX-2選擇性非類固醇消炎劑（NSAID）市場

第18章：中國COX-2選擇性非類固醇消炎劑（NSAID）市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-5D340F440BAE

The COX-2 Selective NSAIDs Market was valued at USD 8.66 billion in 2025 and is projected to grow to USD 9.15 billion in 2026, with a CAGR of 5.71%, reaching USD 12.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.66 billion
Estimated Year [2026] USD 9.15 billion
Forecast Year [2032] USD 12.78 billion
CAGR (%) 5.71%

An authoritative overview of the therapeutic role, evolving safety profile, and commercial context shaping selective COX-2 inhibitor strategies in contemporary practice

Selective COX-2 inhibitors have occupied a distinct therapeutic niche since their introduction, offering targeted anti-inflammatory and analgesic effects while aiming to reduce gastrointestinal toxicity associated with non-selective NSAIDs. Their development and commercialization pathways have been shaped by an evolving safety profile, changes in regulatory expectations, and shifting clinical practice patterns. As clinicians balance efficacy against cardiovascular and renal risk considerations, product differentiation increasingly pivots on formulation, route of administration, and real-world safety evidence.

Over the past decade, the landscape has matured from first-generation molecules and market withdrawals to a more cautious, evidence-driven environment where lifecycle management and post-marketing surveillance are critical. Concurrently, digital health tools, telemedicine, and e-pharmacies have altered how patients access prescriptions and adhere to therapy, prompting manufacturers and distributors to rethink engagement models. Patient centricity and prescriber access to comparative effectiveness data now inform adoption decisions as much as pharmacology.

This introduction frames a deeper exploration of market dynamics, regulatory pressures, distribution transformation, and therapeutic competition. The subsequent analysis connects clinical science, supply chain realities, and commercial strategy to inform decision-making for stakeholders operating across routes, dosage forms, and regional markets. It emphasizes the need for integrated approaches that reconcile safety stewardship, formulary positioning, and resilient sourcing in a complex geopolitical and reimbursement environment.

A concise synthesis of the major clinical, commercial, and regulatory forces driving structural change and strategic realignment across the COX-2 selective therapeutic ecosystem

The COX-2 selective NSAIDs landscape is experiencing several transformative shifts that are redefining development priorities and commercialization tactics. Clinical evidence generation has moved beyond pivotal trials to emphasize real-world safety surveillance and longitudinal cardiovascular outcome studies, and this shift has influenced formulary decisions and prescriber confidence. Innovation is no longer limited to new chemical entities; it increasingly encompasses reformulations, alternate delivery systems, and combination approaches that aim to expand the clinical utility of established molecules while mitigating safety concerns.

Concurrently, distribution and access models are being disrupted by digital channels and direct-to-provider supply relationships, which change how patients obtain therapy and how manufacturers manage stocking and replenishment. Supply chain resilience has ascended the strategic agenda, with firms reassessing supplier concentration and geographic risk exposure in response to trade policy volatility and pandemic-era disruptions. Payer scrutiny and value-based contracting are encouraging manufacturers to demonstrate comparative effectiveness and adherence benefits, prompting targeted outcomes research.

Lastly, regulatory expectations are tightening around post-marketing evidence and pharmacovigilance, driving more rigorous safety monitoring and transparent risk communication. These shifts collectively pressure organizations to integrate clinical, commercial, and regulatory strategies, adopt adaptive trial and evidence-generation frameworks, and pursue collaborative partnerships that can accelerate innovation while managing risk.

An evidence-informed appraisal of how the 2025 United States tariff measures altered supply chain economics, sourcing decisions, and distribution resilience for COX-2 selective medicines

Policy shifts in trade and tariff regimes can have material implications across pharmaceutical supply chains, and the United States tariffs announced or implemented in 2025 introduced a new set of considerations for manufacturers, distributors, and healthcare providers. Tariff measures targeting active pharmaceutical ingredients, excipients, or finished goods elevate input cost volatility and erode margin stability for producers that rely on international suppliers. This change has led many organizations to reassess supplier geographies, increase inventory buffers for critical inputs, and explore alternative logistics arrangements to preserve continuity of supply.

Beyond direct cost impacts, tariff-driven uncertainty influences long-term sourcing strategies. Some firms have accelerated nearshoring initiatives or diversified contract manufacturing to higher-resilience partners, while others have engaged in bilateral supplier agreements to lock in pricing and delivery terms. For distributors and pharmacies, especially those with narrow margins, tariff-related cost pressures necessitate renegotiation of procurement contracts and may shorten the window for promotional activity or introduction of new dosage forms.

Clinicians and institutional buyers have responded by emphasizing predictable supply and consistent clinical performance; procurement teams now factor geopolitical risk into tender evaluations and formulary decisions. Regulatory compliance and customs complexity have also increased administrative burdens, requiring enhanced trade compliance capabilities. While these measures do not change the underlying clinical value of selective COX-2 therapies, they influence pricing strategies, supplier selection, and operational investments that ultimately affect availability and patient access across care settings.

A detailed, multi-dimensional interpretation of segmentation drivers spanning routes, dosage forms, product portfolios, indications, channels, and end-user decision contexts

Segment-level insights reveal how route, dosage form, product selection, indication, distribution channel, and end-user dynamics together shape strategic priorities for selective COX-2 therapies. Based on Route, market is studied across Injectable, Oral, and Topical and this tripartite lens clarifies clinical positioning: injectables are often aligned with acute care settings and procedural use, oral forms support chronic outpatient treatment, and topical preparations address localized pain management with a different safety and adherence profile. Based on Dosage Form, market is studied across Capsule, Suspension, and Tablet which influences adherence characteristics, patient preference, and manufacturing complexity; fast-dissolving or extended-release tablet designs can alter dosing frequency and reimbursement discussions.

Product-level differentiation persists and is informed by pharmacology and legacy safety records; based on Product, market is studied across Celecoxib, Etoricoxib, Rofecoxib, and Valdecoxib and each molecule carries unique regulatory histories and perceived risk-benefit narratives that affect clinical uptake and formulary status. Indication-driven demand patterns are significant; based on Indication, market is studied across Ankylosing Spondylitis, Osteoarthritis, and Rheumatoid Arthritis and each condition presents different treatment paradigms, concomitant therapy considerations, and payer expectations regarding long-term safety monitoring.

Distribution and access analyses underscore channel-specific imperatives; based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is further studied across Direct Manufacturer and Third-Party ERetailers and the Retail Pharmacy is further studied across Chain Pharmacy and Independent Pharmacy. These distinctions matter for inventory velocity, promotional strategy, and patient support programs. Finally, stakeholder segmentation by end use clarifies procurement and clinical decision-making; based on End User, market is studied across Clinics, Homecare, and Hospitals. The Clinics is further studied across Outpatient Clinics and Specialty Clinics and the Hospitals is further studied across Private and Public and each subsegment exerts distinct influence over purchasing cycles, tendering behavior, and expectations for clinical support materials. Integrated strategies that reflect this multi-dimensional segmentation are required to match product profiles with clinical settings, payer mandates, and patient preferences.

A pragmatic regional analysis describing how regulatory frameworks, access dynamics, and manufacturing footprints create differentiated opportunities and risks across global markets

Regional dynamics continue to exert a profound influence on clinical adoption, regulatory requirements, and supply chain design for COX-2 selective therapies. In the Americas, regulatory pathways and payer negotiations emphasize cost-effectiveness and real-world outcome evidence, while the U.S. market in particular demonstrates rapid uptake of digital prescribing and e-pharmacy channels that alter patient access patterns. North American manufacturing and distribution infrastructures are increasingly assessed for resilience in light of recent trade policy shifts, and stakeholder engagement frequently centers on pharmacovigilance data transparency and payer-aligned outcome measures.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization across certain jurisdictions contrasts with localized approval and reimbursement practices in others. Clinicians in several European markets prioritize long-term safety data and head-to-head comparative studies, which can slow adoption in the absence of robust evidence. Meanwhile, pockets of the Middle East and Africa emphasize access and supply stability, prompting distributors to pursue secured contracts and regional warehousing to reduce stockouts and ensure consistent patient access.

In Asia-Pacific, rapid demographic shifts and expanding primary care capacity are driving notable demand for convenient oral and topical therapies. The region also hosts a growing manufacturing base for APIs and finished products, creating both competitive sourcing opportunities and regulatory complexity for exporters. Evolving digital health ecosystems in several Asia-Pacific markets are also reshaping patient engagement and pharmacy fulfillment practices. Across all regions, variability in reimbursement frameworks, clinician guidelines, and supplier networks requires tailored market entry and commercialization strategies that align with local healthcare delivery models and regulatory expectations.

A compact strategic review of how manufacturers and distributors are leveraging portfolio innovation, evidence generation, and supply resilience to defend and expand their foothold

Competitive dynamics among manufacturers, contract developers, and distribution partners are increasingly defined by portfolio agility, evidence-generation capabilities, and supply chain sophistication. Leading pharmaceutical firms and generics manufacturers are focusing on lifecycle management through formulation upgrades, extended-release technologies, and indication expansion where regulatory pathways permit. Strategic partnerships with contract manufacturers and specialty distributors enable rapid scale-up for injectables or novel topical formats, while in-house capabilities remain critical for preserving IP-related process advantages and ensuring quality control.

Market entrants and incumbents alike are investing in real-world evidence platforms to differentiate products on safety and adherence metrics, which supports negotiation with payers and hospital formularies. Commercial differentiation is often achieved through patient support programs that bolster adherence for chronic indications and through provider education initiatives that emphasize appropriate risk mitigation strategies. On the distribution side, an increasing number of companies are optimizing omnichannel strategies that integrate hospital procurement, retail pharmacy relationships, and direct-to-patient online fulfillment to minimize friction across the patient journey.

Finally, corporate strategies include targeted M&A to secure API capacity, selective licensing to widen product reach, and co-development agreements to accelerate access in markets with high regulatory complexity. Firms that combine manufacturing resilience, a clear evidence-generation roadmap, and channel-specific commercialization approaches are best positioned to navigate safety sensitivities while sustaining competitive advantage.

A concise set of prioritized, implementable recommendations designed to fortify supply resilience, evidence generation, and commercial differentiation for COX-2 therapies

Industry leaders should adopt a set of pragmatic, high-impact actions that align clinical value with operational resilience and commercial execution. First, diversify supplier networks for critical intermediates and finished goods to mitigate geopolitical and tariff-related disruptions, while implementing contractual safeguards that lock in lead times and quality standards. Parallel investments in dual-sourcing and regional manufacturing options will reduce exposure to single-point failures and enhance responsiveness to demand shifts.

Second, prioritize evidence strategies that combine randomized trial data with robust real-world outcomes and pharmacovigilance programs to address safety concerns and support favorable formulary placement. Third, accelerate development of differentiated formulations and delivery systems-such as topical preparations with reduced systemic exposure or oral formulations that improve adherence-to strengthen clinical positioning and reimbursement negotiations. Fourth, deepen engagement with payers and large institutional buyers through value-based contracting pilots and outcome-linked agreements that align reimbursement with demonstrated patient benefit.

Finally, modernize commercial operations by integrating digital channels into the sales mix, tailoring messaging to channel-specific stakeholders, and investing in provider education that clarifies appropriate patient selection and risk mitigation. Taken together, these recommendations reduce supply and regulatory risk while creating defensible clinical and commercial differentiation that supports long-term sustainability.

A transparent and replicable mixed-methods research framework combining expert interviews, regulatory review, clinical literature synthesis, and supply chain mapping

The underlying research approach combines qualitative and quantitative techniques to ensure findings are grounded in multiple, corroborating data streams. Primary inputs included structured interviews with clinicians, procurement officers, regulatory specialists, and commercial leaders to capture frontline insights on prescribing behavior, formulary decision criteria, and supply chain constraints. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public pharmacovigilance databases to triangulate safety signals and therapeutic positioning.

Operational analyses relied on supply chain mapping and trade flow assessments to evaluate sourcing concentration and logistics vulnerabilities, supplemented by a review of recent policy changes and tariff announcements that could affect cost structures and lead times. Channel-level dynamics were informed by pharmacy dispensing trends and e-pharmacy adoption studies, while end-user perspectives were validated through stakeholder workshops and scenario testing. Throughout the project, findings were iteratively validated with subject-matter experts to refine assumptions and ensure practical relevance.

The methodology emphasizes transparency in source selection and analytical assumptions, and includes appendices that document interview protocols, search strategies, and criteria for inclusion of clinical and regulatory materials. This mixed-methods approach supports robust conclusions about strategic imperatives without relying on proprietary third-party estimates, and it enables replication of key analytical steps by informed stakeholders.

A succinct conclusion emphasizing the imperative to pair clinical credibility with operational and commercial agility to preserve access and value for selective COX-2 therapies

Selective COX-2 inhibitors remain strategically significant within pain and inflammation management, but their future trajectory is determined less by a single factor than by the interplay among safety evidence, supply reliability, regulatory expectations, and evolving access channels. Clinical differentiation through formulation and route optimization, together with rigorous real-world safety monitoring, will be central to maintaining prescriber confidence. At the same time, commercial success depends on resilient sourcing strategies and adaptive distribution models that can absorb policy and geopolitical shocks.

Organizations that invest in both clinical evidence and operational robustness will be better positioned to secure favorable formulary outcomes and to respond to payer demands for demonstrable value. The confluence of digital channel growth, heightened payer scrutiny, and tariff-induced cost pressures creates both risks and opportunities: firms that act decisively on diversification, evidence generation, and targeted patient support will convert complexity into competitive advantage. The conclusion is clear: aligning clinical credibility with supply chain and commercial agility is essential to sustaining long-term access and value for selective COX-2 therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COX-2 Selective NSAIDs Market, by Route

  • 8.1. Injectable
  • 8.2. Oral
  • 8.3. Topical

9. COX-2 Selective NSAIDs Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Suspension
  • 9.3. Tablet

10. COX-2 Selective NSAIDs Market, by Product

  • 10.1. Celecoxib
  • 10.2. Etoricoxib
  • 10.3. Rofecoxib
  • 10.4. Valdecoxib

11. COX-2 Selective NSAIDs Market, by Indication

  • 11.1. Ankylosing Spondylitis
  • 11.2. Osteoarthritis
  • 11.3. Rheumatoid Arthritis

12. COX-2 Selective NSAIDs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
    • 12.2.1. Direct Manufacturer
    • 12.2.2. Third-Party ERetailers
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. COX-2 Selective NSAIDs Market, by End User

  • 13.1. Clinics
    • 13.1.1. Outpatient Clinics
    • 13.1.2. Specialty Clinics
  • 13.2. Homecare
  • 13.3. Hospitals
    • 13.3.1. Private
    • 13.3.2. Public

14. COX-2 Selective NSAIDs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COX-2 Selective NSAIDs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COX-2 Selective NSAIDs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COX-2 Selective NSAIDs Market

18. China COX-2 Selective NSAIDs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AstraZeneca PLC
  • 19.7. Bayer AG
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Eli Lilly and Company
  • 19.10. GlaxoSmithKline plc
  • 19.11. Johnson & Johnson
  • 19.12. Merck & Co. Inc.
  • 19.13. Novartis AG
  • 19.14. Pfizer Inc.
  • 19.15. Roche Holding AG
  • 19.16. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 242. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)